Avalo Therapeutics, Inc. · NASDAQ:AVTX

Avalo Therapeutics — Investor Presentation (May 2022)

22 slides from Avalo Therapeutics's investor presentation, May 24, 2022

  1. Slide 1: Avalo Therapeutics May 2022 Corporate Presentation

    1 © Copyright 2022. Avalo Therapeutics. All rights reserved. FOR DISCUSSION PURPOSES ONLY Avalo Therapeutics, Inc. May 2022 Corporate Presentation (AVTX) Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    2 © Copyright 2022. Avalo Therapeutics. All rights reserved. This presentation may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are su

  3. Slide 3: Experienced Management Team

    3 © Copyright 2022. Avalo Therapeutics. All rights reserved. Experienced Management Team Decades of successful leadership, product development, commercialization in pharma and biotech *Presenter Garry A. Neil, MD President, Chief Executive Officer* Lisa Hegg, PhD SVP, Program Management and Corporat

  4. Slide 4: Avalo Therapeutics (AVTX)

    4 © Copyright 2022. Avalo Therapeutics. All rights reserved. Avalo Therapeutics (AVTX) 1mAb: monoclonal antibody; 2POC: Proof of concept studies; 3COVID-19 ARDS: SARS-COV2 associated acute respiratory distress syndrome (ARDS); 4IBD: Inflammatory bowel disease; 5NEA: Non- eosinophilic asthma; 6PEAK t

  5. Slide 5: Avalo 2022 Corporate Highlights

    5 © Copyright 2022. Avalo Therapeutics. All rights reserved. New management team: Experienced experts who know the pipeline and people Drive value for shareholders: Allocate capital to most promising programs – Focus on highest value indications for promising novel biologics: AVTX-002 and AVTX-007 –

  6. Slide 6: Clinical-Stage Pipeline

    6 © Copyright 2022. Avalo Therapeutics. All rights reserved. Clinical-Stage Pipeline * The Company is considering a possible randomized, double-blind, placebo-controlled clinical trial in moderate-to-severe refractory patients with IBD ** Further development of AVTX-002 for treatment of COVID-19 ARD

  7. Slide 7: AVTX-002 (Anti-LIGHT mAb)

    7 © Copyright 2022. Avalo Therapeutics. All rights reserved. AVTX-002 (Anti-LIGHT mAb)

  8. Slide 8: AVTX-002: First-in-class anti-LIGHT (TNFSF14) mAb

    8 © Copyright 2022. Avalo Therapeutics. All rights reserved. • Fully human monoclonal antibody (mAb) to LIGHT • POC in 2 indications: COVID-19 ARDS & IBD1 • Currently in phase 2 for non-eosinophilic asthma (NEA) AVTX-002: First-in-class anti-LIGHT (TNFSF14) mAb *Worldwide rights licensed from Kyowa

  9. Slide 9: LIGHT is a Key Driver of Acute & Chronic Inflammation

    9 © Copyright 2022. Avalo Therapeutics. All rights reserved. LIGHT is a Key Driver of Acute & Chronic Inflammation • LIGHT/TNFSF14 is an immunoregulatory cytokine • Critical for neutrophil, NK, T and B cell function • 2 primary receptors: LTβR, HVEM receptors • Pivotal role in lung, GI tract, & othe

  10. Slide 10: AVTX-002 Significantly Reduced Respiratory Failure and Mortality in Phase 2 POC COVID-19 ARDS Study

    10 © Copyright 2022. Avalo Therapeutics. All rights reserved. AVTX-002 Significantly Reduced Respiratory Failure and Mortality in Phase 2 POC COVID-19 ARDS Study Perlin, D. S. et al. Randomized, double-blind, controlled trial of human anti-LIGHT monoclonal antibody in COVID-19 acute respiratory dist

  11. Slide 11: AVTX-002 POC in COVID-19 ARDS

    11 © Copyright 2022. Avalo Therapeutics. All rights reserved. • A single dose rapidly reduced serum free-LIGHT levels by ⋍ 85%1 • Well-tolerated; no increase in serious adverse events vsplacebo • Evidence of clinically important anti-inflammatory effect in the lung • Granted Fast Track Designation b

  12. Slide 12: AVTX-002 Non-Eosinophilic Asthma (NEA)

    12 © Copyright 2022. Avalo Therapeutics. All rights reserved. FOR DISCUSSION PURPOSES ONLY AVTX-002 Non-Eosinophilic Asthma (NEA)

  13. Slide 13: Non-Eosinophilic Asthma (NEA)

    13 © Copyright 2022. Avalo Therapeutics. All rights reserved. Non-Eosinophilic Asthma (NEA) 1. Asthma and Allergy Foundation of America. Asthma facts and figures. https://www.aafa.org/asthma-facts/. Accessed January 3, 2022. 2. McGrath KW et al. Am J Resp Crit Care Med. 2012;185(6):612-619. 3. Jiang

  14. Slide 14: AVTX-002 for Treatment of NEA: PEAK Trial Design

    14 © Copyright 2022. Avalo Therapeutics. All rights reserved. Key Secondary/Exploratory EndpointsPrimary Endpoint Estimated Enrollment: n=80 AVTX-002 8 mg/kg (max 600 mg) q4wks (n=40) AVTX-002 for Treatment of NEA: PEAK Trial Design • Time to exacerbation • Change in FEV1 ‡ from baseline • Proportio

  15. Slide 15: Efficacy Signal Observed in Crohn's Disease Phase 1B Study

    15 © Copyright 2022. Avalo Therapeutics. All rights reserved. • Open-label, uncontrolled study in patients with moderate-to-severe Crohn’s disease who previously failed anti-TNFα mAb1 and other biologics • Rapid reduction in serum free LIGHT levels • Well-tolerated: no drug-related serious adverse e

  16. Slide 16: AVTX-803 Leukocyte Adhesion Deficiency Type II

    16 © Copyright 2022. Avalo Therapeutics. All rights reserved. AVTX-803 Leukocyte Adhesion Deficiency Type II (LAD II, also known as SLC35C1-CDG)

  17. Slide 17: AVTX-803: Leukocyte Adhesion Disorders (LAD II)

    17 © Copyright 2022. Avalo Therapeutics. All rights reserved. AVTX-803: Leukocyte Adhesion Disorders (LAD II) LAD II (SLC35C1-CDG) Pathophysiology LAD Type II: Absence of sialyl Lewis X of E-selectin (SLC35C1 mutation) • Type II (LAD II) caused by LOF mutation in SLC35C1 gene resulting in the inabil

  18. Slide 18: AVTX-803 for LAD II: LADDER Trial Design

    18 © Copyright 2022. Avalo Therapeutics. All rights reserved. Key Secondary/Exploratory EndpointsPrimary Endpoint Estimated Enrollment: n=2 AVTX-803 (L-fucose) for LAD II (SLC35C1-CDG): LADDER Trial Design *100-300 mg/kg up to 5x/d based on clinical response • Restoration of sialyl Lewis X biomarker

  19. Slide 19: Clinical-Stage Pipeline

    19 © Copyright 2022. Avalo Therapeutics. All rights reserved. Clinical-Stage Pipeline * The Company is considering a possible randomized, double-blind, placebo-controlled clinical trial in moderate-to-severe refractory patients with IBD ** Further development of AVTX-002 for treatment of COVID-19 AR

  20. Slide 20: Finance Update

    20 © Copyright 2022. Avalo Therapeutics. All rights reserved. Finance Update

  21. Slide 21: Financial & Investor Information

    21 © Copyright 2022. Avalo Therapeutics. All rights reserved. NASDAQ: AVTX Financial & Investor Information The following data is as of March 31, 2022: • Cash – $38.5M* • Outstanding common shares – 112.8M • Fully diluted shares – 136M • Average daily trading volume – 0.5M Key Financial Highlights *

  22. Slide 22: 2022: A Transformational Year for Avalo

    22 © Copyright 2022. Avalo Therapeutics. All rights reserved. New Management Team and Pipeline Focus Multiple Meaningful Clinical Catalysts • AVTX-002 NEA data from PEAK trial (80-patient Phase 2 trial) in 4Q22 • AVTX-803 LAD II (SLC35C1-CDG) pivotal data from LADDER trial in 4Q22 Business Developme

Avalo Therapeutics — Investor Presentation (May 2022) on 6ix